Vext Announces Continued Growth in Q1 2022
May 30th, 2022
News, Top News
- Revenue of $10.8 million, +16% sequentially
- Adjusted EBITDA of $3.9 million, + 15% sequentially
- Cash flow from operations of $3.1 million
- The Company will hold a conference call and webcast on Tuesday, May 31, 2022 at 8am ET to review its financial results.
VANCOUVER, BC, May 30, 2022 /CNW/ – Vext Science, Inc. (“VEXT” or the “Company”) (OTCQX: VEXTF) (CSE: VEXT) a cannabinoid brand leader based in Arizona, leveraging its core expertise in extraction, manufacturing, cultivation and marketing to build a profitable multi-state footprint, today reported its financial results for the period ended March 31, 2022. All currency references used in this news release are in U.S. currency unless otherwise noted.
Summary Financial Results (unaudited)
|Q1 2022||Q4 2021||Q1 2021|
|Gross margin before impact of biological assets (%)||75%||42%||45%|
|Adjusted Gross Margin (%)1,*||57%||42%||45%|
|Adjusted EBITDA margin (%)1||36%||36%||33%|
|*Adjusted Gross Margin is adjusted for the one-time fair value adjustment to inventory made as a result of Vext’s transition to a for-profit operating and accounting model. The Company does not expect to report Adjusted Gross Margin on an ongoing basis.|
Eric Offenberger, CEO of Vext commented, “Q1 marked an excellent start to the year for Vext, as our team continued to invest in targeted promotions, while maintaining solid gross margins. An efficient operating model, product positioning and category focus will continue to be key success factors in 2022 as consumer-facing industries grapple with the impact of inflation on consumer discretionary income. Vext’s operating model, which has been designed to maintain rigorous cost control, generated growth in Adjusted EBITDA of 15% compared to Q4. Many brands are aimed at the high end of the market, and while there is room for those, our Vapen line of products, which consistently ranks as one of Arizona’s leading brand portfolios, is positioned to deliver high quality at a price that represents consistent value and delivers profitability to the Company.”
Mr. Offenberger continued, “We expect the remainder of 2022 to be an important period for Vext, as we continue to grow in Arizona, and initiate further expansion in Ohio, beginning with the expected approval of our first dispensary license in the state, through a joint venture, during the summer. Despite macro challenges, the current market environment will continue to present opportunities for Vext. We are positioned to gain market share as other operators struggle, backed by a strong balance sheet, ongoing cash flow generation, and a team that has proven its ability to execute. We will take the right steps to continue building loyalty with our customers, and value for our shareholders.”
Summary of Recent Operating Developments
- As of January 1, 2022, Vext transitioned from a not-for-profit operating and accounting framework to a for-profit framework in the state of Arizona. Previously, the Company operated two dispensaries in Phoenix and as of Q1 2022, Vext now has ownership of these dispensaries and they are reflected on its balance sheet. In addition, during Q1, Vext brought the biological assets of the dispensaries on to its balance sheet under IAS 41.
- Senior financial and operations executive Daniel Engel joined the Company on May 2, 2022, as the Company’s CFO.
- In Q1, the Company completed expansions of its cultivation facility in Prescott Valley, bringing Vext’s total indoor cultivation footprint to 24,000 square feet.
Q1-2022 Financial Results Conference Call
Vext will host a conference call and webcast on Tuesday, May 31, 2022 at 8am ET to discuss its first quarter financial results.
Date: May 31, 2022 | Time: 8:00am ET
Participant Dial-in: 416-764-8609 or 888-390-0605
Replay Dial-in: 416-764-8677 or 1-888-390-0541
Conference ID: 07179410
Playback #: 179410 (Expires on June 14, 2022)
Listen to webcast: https://bit.ly/3GquaGE
Non-IFRS Financial Measure
The Company has provided certain non-IFRS financial measures including “Gross margin”, “Adjusted EBITDA” and “Adjusted EBITDA margin”. These non-IFRS financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company defines “Gross margin” as Gross Profit divided by Revenue. The Company defines “Adjusted EBITDA” as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines “Adjusted EBITDA margin” as Adjusted EBITDA divided by Revenue.
The Company has provided these non-IFRS financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental non-IFRS financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. The following tables provide a reconciliation of each of the non-IFRS measures to its closest IFRS measure.
The following information provides reconciliations of the supplemental non-IFRS financial measure presented herein to the most directly comparable financial measure calculated and presented in accordance with IFRS.
Gross Margin Before Impact of Biological Assets and Adjusted Gross Margin
Gross Margin Before Impact of Biological Assets is defined as: Gross Profit Before Impact of Biological Assets, divided by Revenue.
Adjusted Gross Margin is defined as: Gross Margin Before Impact of Biological Assets, adjusted for one-time inventory fair value adjustment, divided by Revenue.
|Change in Fair Value of Biological Assets||($1,216,152)|
|Gross Profit Before Impact of Biological Assets||$8,050,113|
|Relative fair value adjustment to inventory||($1,900,000)|
|Adjusted Gross Profit||$6,150,113|
|Gross Margin Before Impact of Biological Assets||75%|
|Adjusted Gross Margin||57%|
|Q1 2022||Q4 2021||Q1 2021|
|Net income after taxes||$3,458,230||$1,085,087||$1,139,077|
|Depreciation & amortization||$1,471,310||$939,470||$718,394|
|Share (Profit)/Loss on Joint Ventures||$177,399||$130,860||$303,157|
|Gain on derecognitition of Right-of-Use Asset||–||–||–|
|(Gain)/Loss on Investment||–||$212,675||–|
|Change in fair value of Biological Assets||($1,216,152)||–||–|
|Relative fair value adjustment to inventory*||($1,900,000)||–||–|
|*Related to acquisition of the dispensaries|
About VEXT Science, Inc.
Vext Science, Inc. is a US-based Cannabis THC and Hemp cannabinoid products company manufacturing THC cartridges, concentrates, edibles and accessories under the Vapen™ Brand, and Hemp based products under the Pure Touch Botanicals brand as well as the Vapen CBD brand. Based in Arizona, Vext Science, Inc. has one of the leading THC concentrates, edibles, and distillate cartridge brands sold in most of the state’s 100+ dispensaries. Herbal Wellness Center is one of Arizona’s leading dispensaries and we execute all aspects of the cultivation, extraction, edibles infusion and manufacturing processes which insures a product of the highest quality and purity. Product quality and purity are core to our marketing strategy. Vext Science, Inc. is executing its business growth by leveraging experience and expertise in extractions, product manufacturing, and marketing to expand in the U.S. through revenue and profit-sharing joint venture partnerships. For more information visit our website at www.VextScience.com or connect with us on LinkedIn and Twitter.
Forward Looking Statements
This news release contains “forward-looking statements”. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation: the Company’s outlook for and expected operating margins, capital allocation and other financial results; statements relating to the business and future activities of, and developments related thereto, the Company after the date of this news release; statements relating to the business and future activities of, and developments related thereto, the Company after the date of this news release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations regarding cultivation and manufacturing capacity; expectations of market size and growth in the U.S. and the states in which the Company operates; inflation pressures; the timeline to buildout the Eloy cultivation facility, the timeline to transition an operating cannabis dispensary to the Joint Venture; expectations for other economic business or competitive factors related to the Company; the Company’ business outlook, those listed in the annual information form of the Company dated September 17, 2020, the short form prospectus and the other filings made by the Company with the Canadian securities’ regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
Chief Executive Officer
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.